About: Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs
Creator	Moreno, Estefanía Almirall, Miriam Antón, Susana Añez, Gustavo Barceló-Bru, Mireia Borrell, Helena Caparrós-Ruiz, Raquel De Agustín, Juan Erra, Alba Espartal, Esther Julià, Antonio López-Corbeto, Mireia López-Lasanta, María Marsal, Sara Michelena, Xabier Pascual-Pastor, María Pluma, Andrea Segura, Jordi Serrat, Mayte Trallero-Araguás, Ernesto
Source	Elsevier; Medline; PMC
abstract	OBJECTIVES: To investigate the incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases receiving targeted biologic and synthetic disease modifying anti-rheumatic drugs (tDMARDs) and to explore the possible effect of these treatments in the clinical expression of COVID-19. METHODS: A cross-sectional study comprising of a telephone survey and electronic health records review was performed including all adult and paediatric patients with rheumatic diseases treated with tDMARDs in a large rheumatology tertiary centre in Barcelona, Spain. Demographics, disease activity, COVID-19 related symptoms and contact history data were obtained from the start of the 2020 pandemic. Cumulative incidence of confirmed cases (SARS-CoV-2 positive PCR test) was compared to the population estimates for the same city districts from a governmental COVID-19 health database. Suspected cases were defined following WHO criteria and compared to those without compatible symptoms. RESULTS: 959 patients with rheumatic diseases treated with tDMARDs were included. We identified 11 confirmed SARS-CoV-2 positive cases in the adult cohort and no confirmed positive cases in the paediatric cohort. COVID-19 incidence rates of the rheumatic patient cohort were very similar to that of the general population [(0.48% (95% CI 0.09 to 8.65%)] and [0.58% (95% CI 5.62 to 5.99%)], respectively. We found significant differences in tDMARDs proportions between the suspected and non-suspected cases (p=0.002). CONCLUSION: Adult and paediatric patients with rheumatic diseases on tDMARDs do not seem to present a higher risk of COVID-19 or a more severe disease outcome when compared to general population.
has issue date	2020-05-16(xsd:dateTime)
bibo:doi	10.1016/j.semarthrit.2020.05.001
bibo:pmid	32425260
has license	no-cc
sha1sum (hex)	4bd7744e1fc4a121de2f9161a459cbf33d57f5ac
schema:url	https://doi.org/10.1016/j.semarthrit.2020.05.001
resource representing a document's title	Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs
has PubMed Central identifier	PMC7229730
has PubMed identifier	32425260
schema:publication	Semin Arthritis Rheum
resource representing a document's body	covid:4bd7744e1fc4a121de2f9161a459cbf33d57f5ac#body_text
is schema:about of	named entity 'targeted' named entity 'COVID-19' named entity 'Journal' named entity 'rheumatic diseases' named entity 'randomized clinical trials' named entity 'COVID' named entity 'IL-6' named entity 'Spain' named entity 'COVID-19' named entity 'Odds ratio' named entity 'clinical presentation' named entity 'randomised clinical trials' named entity 'infection' named entity 'anakinra' named entity 'Paediatric' named entity 'IL-1' named entity 'COVID-19 pandemic' named entity 'Rheumatology' named entity 'COVID' named entity 'IL-6' named entity 'clinical diagnosis' named entity 'WHO' named entity 'pneumonia' named entity 'PCR testing' named entity 'COVID' named entity 'SARS-CoV-2' named entity 'persistent cough' named entity 'general population' named entity 'comorbidities' named entity 'disease outcome' named entity 'IMID' named entity 'general population' named entity 'pneumonia' named entity 'rheumatic disease' named entity 'SARS-CoV-2' named entity 'inflammatory cytokine' named entity 'epidemiological' named entity 'COVID' named entity 'NICE' named entity 'WHO' named entity 'SARS-CoV-2' named entity 'pandemic disease' named entity 'NICE' named entity 'IL-6' named entity 'fever' named entity 'Barcelona' named entity 'off-label' named entity 'Vall d'Hebron University Hospital' named entity 'epidemiological studies' named entity 'etanercept' named entity 'abatacept' named entity 'IMID' named entity 'DMARDs' named entity 'American College of Rheumatology' named entity 'psoriatic arthritis' named entity 'IMID' named entity 'COVID' named entity 'comorbidities' named entity 'electronic health records' named entity 'rheumatic disease' named entity 'general population' named entity 'antirheumatic drugs'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software